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The eﬃcacy of AntiOxidant Biofactor (AOB®) for the management of apparently healthy subjects with 
chronic hepatitis C infection was investigated.  A total of 60 subjects (35 males,  25 females) partici-
pated in the trial.  AOB was given orally in 2 packs (3g per pack) 3 times per day.  17 subjects had 
taken AOB for 3 years,  31 subjects up to 2 years,  and 41 subjects up to one year.  The initial mean 
(SD) serum alamine aminotransferase (ALT) level was 46.3±35.4IU/L,  and signiﬁcant (p＜0.05,  
paired t-test) reductions in the mean serum ALT levels were observed at 6 months (38.6±21.5IU/L),  
18 months (31.9±18.1IU/L),  2 years (31.2±14.6IU/L),  and 3 years (28.0±15.9IU/L).  Those presenting 
with high serum ALT levels (30 subjects) demonstrated signiﬁcant levels (p＜0.05,  paired t-test) of 
reduction in the mean serum ALT levels at 6,  12,  18,  24,  and 36 months of treatment.  No side eﬀects 
were observed and the AOB treatment was well tolerated by all subjects.
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epatitis C virus (HCV),  an RNA virus,  was ﬁrst 
identiﬁed in the USA in 1989 as a major caus-
ative agent of post-transfusion non-A,  non-B hepatitis 
[1].  The World Health Organization (WHO) has 
estimated that 170 million persons are chronically 
infected with HCV [2].  Although the acute infection 
is usually asymptomatic and may not be recognized 
clinically,  the subsequent chronic infection is usually 
life-long and may lead to chronic liver disease and,  
ultimately,  liver cirrhosis and hepatocellular carci-
noma.  In fact,  in Japan,  where the incidence of hepa-
titis B virus infection is low,  HCV infection has been 
reported as the single most important etiological fac-
tor for the development of hepatocellular carcinoma 
[3].
　 The problem of transfusion-associated Non-A 
Non-B (NANB) hepatitis had been investigated in 
Myanmar since the mid-80s,  with one study reporting 
that nearly 20ｵ of blood transfusion recipients had 
contracted NANB hepatitis in that country [4].  It has 
been reported that hepatitis C virus infection is pres-
ent in one-third of patients with hepatocellular carci-
noma and in 2.5ｵ of apparently healthy subjects [5].  
The prevalence of hepatitis C seropositivity among 
102,632 blood donors at the major blood banks in 
Yangon was found to be 2.84ｵ (Paing Soe et al.,  
H
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presented at the Myanmar Health Research Congress,  
Yangon,  2000).  The prevalence of antibody to hepati-
tis C virus (anti-HCV) was found to be 2.8ｵ among 
569 subjects,  aged 3 months to 74 years,  residing in 
Yangon [6].  In recent study of 349 subjects aged 12 
months to 70 years in a northeast border town of 
Myanmar,  the overall anti-HCV positivity rate was 
even higher,  or 13.5ｵ [7].  Based on these ﬁndings,  
it could be estimated that there are more than 1 mil-
lion persons with hepatitis C seropositivity in 
Myanmar.
　 Clinically,  the proportion of HCV-infected patients 
who go on to develop chronic liver disease exceeds 
80ｵ,  with up to 20ｵ of chronic HCV cases pro-
gressing to liver cirrhosis,  and 1-5ｵ of HCV-
infected patients developing HCC over a period of 
20-30 years.  However,  the treatment options for 
HCV are limited and expensive.  Therapy with inter-
feron (IFN) alpha/beta subtypes or in combination 
with antiviral drugs such as guanosine analogue 
(Ribavirin) are generally considered as the ﬁrst line 
treatment for chronic HCV infection.  However,  high 
doses of IFN may be associated with the development 
of many dose-related side eﬀects [8].  A report that 
clastogenic factors were present in the plasma of 19 
of 20 chronic hepatitis C patients but in none of the 
control subjects has led to interest in the use of anti-
oxidants in the management of chronic hepatitis C 
patients [9].
　 Clastogenic― i.e.,  chromosome-damage inducing―
substances are present in the plasma of patients with 
a variety of pathological conditions accompanied by 
oxidative stress.  These include irradiated persons,  
patients with inﬂammatory diseases of the connective 
tissue,  the gut,  the liver or the nervous system,  and 
patients with HIV diseases [10].  Researchers from 
Paris conducted a clinical trial comparing Anti-
Oxidant Biofactor (AOB®) to placebo in patients with 
chronic hepatitis C.  They found that AOB treatment 
inhibited lipid peroxidation,  increased glutathione 
levels and signiﬁcantly reduced serum alamine amin-
otransferase (ALT) levels [11].  This study,  together 
with studies on several other diseases [12,  13],  has 
encouraged scientists to investigate the eﬀects of 
AOB® in hepatitis infection.
　 We conducted the present study to determine the 
eﬃcacy of AOB® for the long-term treatment of 
healthy hepatitis C-infected patients in Myanmar.  The 
primary objective of the study was to determine the 
eﬀects of AOB® on liver enzyme levels,  and the sec-
ondary objectives were to determine the acceptance of 
AOB by the patients and to observe the side eﬀects.
Subject and Methods
　 Study design. This open-label,  single-arm,  
non-comparative clinical trial was carried out in 
Yangon,  Myanmar during 2005 and 2008.  Prior to the 
conduct of the study,  ethical permission was obtained 
from the Institutional Ethical Committee of the 
Department of Medical Research (Lower Myanmar),  
and the study was conducted in accordance with the 
principles of Good Clinical Practice and the Declara-
tion of Helsinki.
　 Subjects. Subjects were asymptomatic healthy 
individuals attending the Hepatitis Carrier Clinic of 
the Department of Medical Research (Lower 
Myanmar),  Yangon,  Myanmar,  with seropositivity to 
hepatitis C virus.  The subjects were adequately 
informed about the objectives and details of the clini-
cal trial and characteristics of AOB and were oﬀered 
inclusion in the study.  Those willing to participate 
were asked to sign a consent form.  The subjects were 
screened by history and physical examination before 
entering the study.  All included patients were in 
apparently good health,  were more than 18 years of 
age,  and had been diagnosed HCV antibody-positive.  
Both men and women,  and individuals with a broad 
range of liver enzyme levels were included.  Exclusion 
criteria were (a) alcohol intake of more than 60g/day 
and/or smoking of more than 15 cigarettes or 30g of 
tobacco/day,  (b) complications of liver disease such as 
cirrhosis or hepatocellular carcinoma,  (c) HIV infec-
tion,  (d) pregnancy,  (e) lactation,  and (f) the use of 
any antioxidant or hepatotoxic drug over the previous 
3 months.
　 AntiOxidant Biofactor (AOB®). AOB® 
(AOA Company,  Kobe,  Japan) contains many biofac-
tors and exerts many bioeﬀects as a result of the 
roasting and fermentation of the raw materials.  The 
raw materials of AOB are rice germ (18ｵ),  rice bean 
(15ｵ),  soybean (20ｵ),  adlay millet (7.5ｵ),  sesame 
(4ｵ),  wheat (9ｵ),  green leaves extract (Japanese 
radish leaf; 10ｵ),  and citrus junos (Chinese lemon 
juice: 2.5ｵ),  which are mixed together with addi-
tional sesame extract.  The ingredients are roasted 
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and fermented according to the traditional techniques 
used in Chinese herbal medicine.
　 Trial procedure. Each patient was given an 
explanation regarding the nature of study,  and only 
those who gave voluntary consent were included in the 
study.  Each patient had the right to withdraw from the 
study at any stage.  A complete physical examination 
was performed and a complete medical history was 
obtained at baseline using standard proformas.  
Abdominal ultrasonography ﬁndings were recorded and 
a detailed physical examination was carried out to 
exclude serious medical problems including liver cir-
rhosis and hepatocellular carcinoma.  Venous blood 
samples (3ml) were collected to conﬁrm HCV sero-
positivity by HCV PAII test kits (Ortho-Clinical 
Diagnostic; Fujirebio Inc.,  Tokyo,  Japan).  Hepatitis 
B surface antigen was detected using DMR ELISA 
and ALT levels were measured using ALT kits 
(Nichimen Company,  Tokyo,  Japan).
　 Assessment. Analysis was conducted for sub-
jects who had taken AOB for more than 3 months.  
The following patients were excluded from the analy-
sis: those who did not adhere to the schedule of clinic 
visits; those who required additional antiviral thera-
py; those who received medications with a potential 
eﬀect on immunity; those who failed to meet the inclu-
sion criteria; and those who met one of the exclusion 
criteria either before or after the start of the study.
　 Sample size calculation. Sample size calcula-
tion was based on the assumption of a natural reduc-
tion of ALT levels in 20ｵ of subjects taking any 
treatment and a reduction of ALT levels in 70ｵ of 
subjects taking AOB.  A sample size of 36 subjects 
was considered suﬃcient with an alpha error of 0.05 
and a power of 0.8 [15].
　 Statistical analysis. Statistical analysis was 
carried out using MINITAB® 14.1,  (Minitab Corpora-
tion,  State College,  PA,  USA).  For continuous 
variables,  descriptive statistics (mean＋standard 
deviation) and for discrete variables,  counts with 
percentages are presented.  Successful treatment was 
deﬁned as a signiﬁcant reduction in ALT levels at 12,  
24 and 36 months of therapy.  ALT levels were com-
pared using a pair-wise t-test (values of p＜0.05 were 
considered statistically signiﬁcant).  Those with initial 
ALT levels higher than or equal to 40IU/L were 
regarded as having high initial ALT levels.
Results
　 Characteristics of the subjects. A total of 77 
subjects volunteered to participate in the study,  and 
60 of these subjects fulﬁlled the criteria for assess-
ment.  Their mean age±SD was 44.52±10.45 years.  
There were 35 males and 25 females.  There was no 
signiﬁcant diﬀerence in the mean age (years) of males 
and females (43.03±9.9 vs 46.6±11.0).  So far,  17 
subjects have ﬁnished 36 months of therapy,  and 31 
subjects have ﬁnished 24 months of therapy (Table 1).
　 Serum ALT levels. The mean serum ALT 
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Table 1　 Changes of serum ALT level by months of AOB therapy with special reference to the initially high ALT subjects
Mean serum ALT levels by months of AOB therapy Subjects with initial ALT＞＝40 IU/L
Months 
of 
therapy
Total 
number 
of 
subjects
Mean ALT 
levels 
± 
SD (IU/L)
Paired
“t” test
T-value
P-value
Number of 
subjects with 
ALT＜40 IU/L 
(Proportion to 
total number %)
Initial 
number 
of 
subjects
Mean ALT 
levels 
± 
SD (IU/L)
Paired 
“t” test 
T-value
P-value
Number of 
subjects
shifted to 
ALT＜40 IU/L
(Proportion to 
initial number %)
Initial 60 46.3±35.4 30 (50.0) 30 65.4±42.0
3 60 41.3±20.3 1.37 NS 35 (58.3) 30 52.2±22.1 1.98 NS 10 (33.3)
6 50 38.6±21.6 2.05 0.046 33 (66.0) 24 48.4±26.2 2.76 0.011 12 (50.0)
9 43 39.3±23.4 2.19 0.034 23 (53.5) 23 47.1±26.0 2.91 0.008 8 (34.8)
12 41 39.6±20.3 1.98 NS 25 (61.0) 22 46.0±22.3 2.81 0.011 8 (36.4)
18 34 31.9±18.5 3.94 0.005 25 (73.5) 18 38.4±21.0 4.51 0.005 11 (61.0)
24 31 31.2±14.6 2.92 0.007 24 (77.4) 17 32.1±15.3 4.09 0.001 13 (76.5)
30 20 33.8±17.2 1.67 NS 15 (75.0) 12 30.7±11.4 3.25 0.008 9 (75.0)
36 17 28.0±16 2.59 0.02 14 (82.4) 11 26.8±13.4 3.65 0.004 9 (81.8)
SD,  Standard deviation; ALT,  alanine aminotransferase.
level on admission was 46.25±35.41IU/L with a 
minimum of 15IU/L and a maximum of 253IU/L.  
The mean±SD ALT levels by months of AOB ther-
apy are shown in Table 1.
　 A detailed analysis was carried out to determine 
the eﬀect of AOB on subjects with high initial ALT 
levels.  A signiﬁcant decrease in the mean serum ALT 
levels was observed from 6 months to 36 months of 
AOB treatment (Table 1,  Fig.  1).
　 Proportion of subjects achieving low levels of 
ALT. The proportion of subjects with a serum 
ALT level less than 40IU/L was assessed.  At the 
start of the trial 30 subjects (50ｵ) had an ALT level 
less than 40IU/L.  An additional increase in the pro-
portion of subjects with an ALT less than 40IU/L 
was seen at each successive treatment time point.  At 
24 months of treatment more than 75ｵ of the subjects 
had achieved low ALT levels (Table 1).
Discussion
　 Hepatitis C infection is an emerging health problem 
in Myanmar.  Although signiﬁcant results have been 
obtained by the national Control of Hepatitis C 
Project,  a considerable population of hepatitis 
C-infected individuals still exists in Myanmar.  Based 
on the prevalence of 2.8ｵ HCV seropositivity in blood 
donors (Paing Soe et al.,  presented at the Myanmar 
Health Research Congress,  Yangon,  2000),  it can be 
estimated that there are more than one million sub-
jects with HCV infection in Myanmar.  Although HCV 
infection can lead to chronic liver diseases and hepa-
tocellular carcinoma,  the treatment options are very 
limited.  In addition,  existing treatments are diﬃcult 
and compliance is essential to achieve results.  Current 
regimens are rigid and certain laboratory tests needs 
to be carried out during management.  Dual therapy 
with interferon and antiviral combinations are the 
standard treatment regimens,  but they are very 
expensive and are not 100ｵ eﬀective [8].  Moreover,  
interferon has to be given by subcutaneous injection 
and is associated with a long list of side-eﬀects includ-
ing ﬂu-like symptoms,  fever and depression.
　 AOB® is composed mainly of natural products and 
no side eﬀects have been reported.  It has been shown 
to inhibit liver injury in endotoxemic rats exposed to 
lipopolysaccharide (LPS).  In that study,  AOB sup-
pressed LPS-induced superoxide generation and 
inhibited the decrease in glutathione levels in the rat 
liver.  The liver enzyme levels were reduced and the 
histology of liver sections showed neither focal necro-
sis nor neutrophil inﬁltration in contrast to the 
untreated controls.  The administration of AOB sig-
niﬁcantly decreased the mortality rate of the endotox-
emic animals [15].  In another study,  researchers 
from Paris conducted a clinical trial comparing AOB® 
to placebo in patients with chronic hepatitis C 15 
patients with chronic hepatitis C infection received 
AOB and 15 received a placebo.  AOB® was taken 
daily at a dose of 2 sachets (3g of powder per sachet) 
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Fig. 1　 The decline in ALT values by the months of AOB treatment in subjects with high initial ALT (dotted line) values and in all sub-
jects (straight line) along with the standard deviation.
3 times a day for a period of 3 months.  ALT and 
AST (aspartate aminotransferase) levels decreased in 
11 of the 15 patients.  Oxidative stress biomarkers,  
aminotransferase levels and viral load were deter-
mined immediately before and after treatment.  
Although a decrease in viral load was not observed,  
ALT and oxidative stress markers were reduced 
[11].
　 Our study has limitations.  Assays for detection of 
oxidative stress,  such as lipid peroxidation,  total 
plasma thiols,  and clastogenic factor tests were not 
available in our laboratory and were not carried out.  
Thus the eﬀect of AOB® on oxidative stress could not 
be demonstrated.  Also,  we were not able to determine 
the changes in liver histopathology,  as liver biopsies 
are not routinely carried out in Myanmar.  Since 
AOB® is not an anti-viral agent,  changes in viral load 
are not expected and were not determined in this 
study.  Moreover,  a previous clinical trial did not 
observe any reductions in the levels of viral load [11].  
Although our paper is preliminary,  it clearly showed 
a reduction of ALP level in association with the dura-
tion of AOB therapy,  and the proportion was fairly 
remarkable after 24 months of therapy in subjects 
with an initially high ALP level (Table 1).
　 Because AOB is a fermented grain supplement,  we 
speculate that one of the possible mechanisms by 
which it combats the progression of hepatitis C is 
through chelation eﬀects on redox active free iron.  
That is,  AOB contains a large proportion of low 
molecular weight components as a result of fermenta-
tion,  and those components―for example,  amino 
acids,  nucleic acids and their derivatives,  which are 
other low molecular weight organic acids―are well-
known metal chelators,  and they will remove or stabi-
lize redox active iron in the liver.  As hepatic iron has 
an unfavorable prognostic value and iron-reduction 
therapy by phlebotomy has a beneﬁcial eﬀect in 
patients with chronic hepatitis C [16,  17],  it is worth 
investigating whether the chelation eﬀect of AOB may 
have beneﬁcial eﬀects in patients with high ALT lev-
els.
　 Drinking tea is a common practice in Myanmar and 
AOB is well accepted as a food supplement by the 
Myanmar people.  The majority of subjects in the pres-
ent study reported that AOB had a pleasant taste and 
increased their sense of well being.  This is an impor-
tant issue,  as it is a known fact that many chronically 
infected HCV patients are severely disabled by the 
non-hepatic manifestations of HCV infection,  mainly 
fatigue [18].  The lack of side eﬀects also helped to 
increase the acceptance of AOB among our study 
population.  From this study,  it could be concluded 
that AOB is beneﬁcial for the management of subjects 
with chronic hepatitis C infection,  especially in sub-
jects with high ALT levels.  The high acceptance and 
lack of side eﬀects could help to reduce the conse-
quences of hepatitis C infection and would be of great 
beneﬁt to individual patients.
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